Cargando…

Long-term safety and efficacy of opicapone in Japanese Parkinson’s patients with motor fluctuations

The double-blind part of the COMFORT-PD (COMt-inhibitor Findings from Opicapone Repeated Treatment for Parkinson’s Disease) study in Japanese levodopa-treated patients with Parkinson’s disease and motor fluctuations found that both opicapone 25 and 50 mg were significantly more effective than placeb...

Descripción completa

Detalles Bibliográficos
Autores principales:	Takeda, Atsushi, Takahashi, Ryosuke, Tsuboi, Yoshio, Nomoto, Masahiro, Maeda, Tetsuya, Nishimura, Akihisa, Yoshida, Kazuo, Hattori, Nobutaka
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Vienna 2021
Materias:	Neurology and Preclinical Neurological Studies - Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7969548/ https://www.ncbi.nlm.nih.gov/pubmed/33630140 http://dx.doi.org/10.1007/s00702-021-02315-1

Ejemplares similares

Randomized, Controlled Study of Opicapone in Japanese Parkinson's Patients with Motor Fluctuations
por: Takeda, Atsushi, et al.
Publicado: (2020)

Pharmacokinetic Comparison of Capsule and Tablet Formulations of Opicapone in Healthy Japanese Subjects: Phase 1 Study
por: Nomoto, Masahiro, et al.
Publicado: (2020)

Effect of Opicapone Tablets on Levodopa and 3‐O‐Methyldopa Pharmacokinetics in Healthy Japanese Subjects: Phase 1 Study
por: Nomoto, Masahiro, et al.
Publicado: (2020)

Long-term effects of safinamide adjunct therapy on levodopa-induced dyskinesia in Parkinson’s disease: post-hoc analysis of a Japanese phase III study
por: Hattori, Nobutaka, et al.
Publicado: (2022)

Long-term safety and efficacy of adjunctive rasagiline in levodopa-treated Japanese patients with Parkinson’s disease
por: Hattori, Nobutaka, et al.
Publicado: (2019)

Long-term, open-label, phase 3 study of rasagiline in Japanese patients with early Parkinson’s disease
por: Hattori, Nobutaka, et al.
Publicado: (2019)

The Effects of Safinamide Adjunct Therapy on Depression and Apathy in Patients With Parkinson's Disease: Post-hoc Analysis of a Japanese Phase 2/3 Study
por: Hattori, Nobutaka, et al.
Publicado: (2022)

The Added Benefit of Opicapone When Used Early in Parkinson's Disease Patients With Levodopa-Induced Motor Fluctuations: A Post-hoc Analysis of BIPARK-I and -II
por: Rocha, José-Francisco, et al.
Publicado: (2021)

The safety/tolerability of opicapone when used early in Parkinson's disease patients with levodopa-induced motor fluctuations: A post-hoc analysis of BIPARK-I and II
por: Rocha, José-Francisco, et al.
Publicado: (2022)

Impact of non-motor fluctuations on QOL in patients with Parkinson’s disease
por: Kakimoto, Asako, et al.
Publicado: (2023)

The real-life effect of catechol-O-methyltransferase inhibition on non-motor symptoms in levodopa-treated Parkinson’s disease: opicapone versus entacapone
por: Leta, Valentina, et al.
Publicado: (2023)

Real‐World Nonmotor Changes in Patients with Parkinson's Disease and Motor Fluctuations: J‐FIRST
por: Watanabe, Hirohisa, et al.
Publicado: (2020)

Gender differences in non-motor fluctuations in Parkinson’s disease
por: Donzuso, Giulia, et al.
Publicado: (2023)

Frequency of Non-motor Symptoms in Parkinson's Patients With Motor Fluctuations
por: Fernandes, Mariana, et al.
Publicado: (2021)

Non-motor symptoms burden in motor-fluctuating patients with Parkinson’s disease may be alleviated by safinamide: the VALE-SAFI study
por: De Masi, Claudia, et al.
Publicado: (2022)

Intestinal Decontamination Therapy for Dyskinesia and Motor Fluctuations in Parkinson's Disease
por: Baizabal-Carvallo, José Fidel, et al.
Publicado: (2021)

Relationship between motor dysfunction and chewing movement in patients with Parkinson's disease: A transversal study
por: Sano, Taisei, et al.
Publicado: (2022)

Collective Expert Perspectives on the Use of Safinamide as Adjunctive Therapy for Parkinson's Disease: Online-Based Delphi Survey
por: Takeda, Atsushi, et al.
Publicado: (2022)

Deep brain stimulation in posterior subthalamic area for Holmes tremor: Case reports with review of the literature
por: Kamo, Hikaru, et al.
Publicado: (2023)

Fatigue in fluctuating Parkinson’s disease patients: possible impact of safinamide
por: Pauletti, Caterina, et al.
Publicado: (2023)

Fluctuations in Parkinson’s disease and personalized medicine: bridging the gap with the neuropsychiatric fluctuation scale
por: Schmitt, Emmanuelle, et al.
Publicado: (2023)

Sustained response in early responders to safinamide in patients with Parkinson's disease and motor fluctuations: A post hoc analysis of the SETTLE study
por: Bhidayasiri, Roongroj, et al.
Publicado: (2023)

Effectiveness and safety of opicapone in Parkinson’s disease patients with motor fluctuations: the OPTIPARK open-label study
por: Reichmann, Heinz, et al.
Publicado: (2020)

Opicapone versus placebo in the treatment of Parkinson’s disease patients with end-of-dose motor fluctuation-associated pain: rationale and design of the randomised, double-blind OCEAN (OpiCapone Effect on motor fluctuations and pAiN) trial
por: Chaudhuri, K. Ray, et al.
Publicado: (2022)

Effect of Opicapone on Levodopa Pharmacokinetics in Patients with Fluctuating Parkinson's Disease
por: Ferreira, Joaquim J., et al.
Publicado: (2022)

The Seasonal Fluctuation of Fatigue in Multiple Sclerosis
por: Grothe, Matthias, et al.
Publicado: (2022)

Motor Function Relating to the Accuracy of Self-Overestimation Error in Community-Dwelling Older Adults
por: Kawasaki, Tsubasa, et al.
Publicado: (2020)

Evaluation of perception threshold and pain in patients with Parkinson’s disease using PainVision(®)
por: Kurihara, Kanako, et al.
Publicado: (2023)

Quality of life: Seasonal fluctuation in Parkinson's disease
por: Wu, Lei, et al.
Publicado: (2023)

Correction to: Effectiveness and safety of opicapone in Parkinson’s disease patients with motor fluctuations: the OPTIPARK open-label study
por: Reichmann, Heinz, et al.
Publicado: (2020)

Motor and non-motor improvements following short-term multidisciplinary day-clinic care in Parkinson´s disease
por: Krause, Patricia, et al.
Publicado: (2022)

Clinical Manifestations and Molecular Backgrounds of Parkinson's Disease Regarding Genes Identified From Familial and Population Studies
por: Nishioka, Kenya, et al.
Publicado: (2022)

Correction: Long-term effects of safinamide adjunct therapy on levodopa-induced dyskinesia in Parkinson’s disease: post-hoc analysis of a Japanese phase III study
por: Hattori, Nobutaka, et al.
Publicado: (2022)

Sleep and non-motor symptoms in Parkinson’s disease
por: Maass, Antonia, et al.
Publicado: (2013)

Increased Neurofilament Light Chain and YKL-40 CSF Levels in One Japanese IBMPFD Patient With VCP R155C Mutation: A Clinical Case Report With CSF Biomarker Analyses
por: Ikeda, Masaki, et al.
Publicado: (2020)

Increased Dynamic Amplitude of Low Frequency Fluctuation in Primary Insomnia
por: Meng, Xianyun, et al.
Publicado: (2020)

Post-Treatment Plasma D-Dimer Levels Are Associated With Short-Term Outcomes in Patients With Cancer-Associated Stroke
por: Nakajima, Sho, et al.
Publicado: (2022)

Intrastriatal Memantine Infusion Dampens Levodopa-Induced Dyskinesia and Motor Deficits in a Mouse Model of Hemiparkinsonism
por: Ogawa, Masatoshi, et al.
Publicado: (2019)

Non-motor symptoms of Parkinson’s disease: the patient’s perspective
por: Breen, Kieran C., et al.
Publicado: (2012)

Interrater reliability of motor severity scales for hemifacial spasm
por: Lee, Ha Yeon, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_i40eec56poe03ujbdgk0mlclkh